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ARTICLE
MTR4 drives liver tumorigenesis by
promoting cancer metabolic switch
through alternative splicing
Lili Yu1,2,7*, Jinchul Kim1,3,7, Lei Jiang2, Bingbing Feng2, Yue Ying2, Kai-yuan Ji1, Qingshuang Tang2,
Wancheng Chen2, Taoyi Mai1, Wenlong Dou2, Jianlong Zhou2, Le-yang Xiang4, Yang-fan He5, Dinghua Yang4,
Qingjiao Li1, Xuemei Fu1,6* & Yang Xu1,2,3*
The metabolic switch from oxidative phosphorylation to glycolysis is required for tumor-
igenesis in order to provide cancer cells with energy and substrates of biosynthesis.
Therefore, it is important to elucidate mechanisms controlling the cancer metabolic switch.
MTR4 is a RNA helicase associated with a nuclear exosome that plays key roles in RNA
processing and surveillance. We demonstrate that MTR4 is frequently overexpressed in
hepatocellular carcinoma (HCC) and is an independent diagnostic marker predicting the poor
prognosis of HCC patients. MTR4 drives cancer metabolism by ensuring correct alternative
splicing of pre-mRNAs of critical glycolytic genes such as GLUT1 and PKM2. c-Myc binds to
the promoter of the MTR4 gene and is important for MTR4 expression in HCC cells, indi-
cating that MTR4 is a mediator of the functions of c-Myc in cancer metabolism. These
findings reveal important roles of MTR4 in the cancer metabolic switch and present MTR4 as
a promising therapeutic target for treating HCC.
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Hepatocellular carcinoma (HCC) has become one of themajor cancers in the world with limited therapeuticoptions and increasing mortality rate1. In contrast to
normal somatic cells that obtain energy primarily from oxidative
phosphorylation (OXPHOS), human cancer cells depend on
glycolysis to obtain energy and substrates for biosynthesis2.
Therefore, the elucidation of the pathways important for cancer
metabolic switch from OXPHOS to glycolysis will provide more
specific therapeutic targets for cancer therapy. While many
oncogenic pathways such as c-Myc pathway play important roles
in promoting cancer metabolic switch by regulating the expres-
sion of metabolic genes3, various types of human cancers exhibit
high levels of heterogeneity and may develop distinct mechanisms
to induce cancer metabolic reprogramming. For example, recent
studies demonstrate that HCC cells expressing wild type p53
depend on p53-PUMA pathway to maintain the metabolic switch
from OXPHOS to glycolysis through PUMA-mediated disruption
of mitochondrial pyruvate carrier-dependent pyruvate uptake4.
The regulation of gene expression can be achieved at many
levels, including the transcriptional and posttranscriptional
mechanisms. The nuclear exosome monitors and degrades RNAs
using RNA-binding cofactor complexes that recruit specific RNA
targets for processing. Two major cofactor complexes, the cyto-
plasmic Ski and nuclear TRAMP complexes, are involved in
recruiting RNAs to exosome5. RNA helicases such as MTR4 are
associated with cofactor complexes and unwind complex RNA
structures to permit the insertion of RNA into exosome for
processing5. MTR4 is present in the TRMAP complex, the
nuclear exosome targeting (NEXT) complex and poly-A tail
exosome targeting (PAXT) complex for RNA decay, suggesting
that MTR4 targets a broad spectrum of RNA and regulates their
stability. MTR4 has not been shown to play important roles in
alternative splicing (AS), but the exosome is involved in chro-
matin remodeling and normal processing of various RNAs such
as pre-mRNA splicing6–9. While the biochemical functions of
MTR4 have been extensively investigated, the physiological roles
of MTR4 in development and disease remain unclear.
Recent studies have demonstrated that various types of human
cancer could develop aberrant AS landscape, contributing to the
tumorigenic processes10. These cancer relevant AS patterns in
human cancer cells could result from the mutations in splicing
sites of pre-mRNAs and regulatory elements or alterations in
spliceosome components11. For example, the abnormal regulation
of the AS events of the key metabolic genes such as PKM1/PKM2
could drive cancer metabolic reprogramming12. Therefore, to
improve the specificity and efficacy of current therapeutic inter-
ventions, it is important to elucidate the mechanisms underlying
the aberrant RNA splicing in order to identify new targets for
suppressing cancer relevant splicing events. Polypyrimidine tract-
binding protein 1 (PTBP1) is an important regulator of AS13. The
binding of PTBP1 to pre-mRNA suppresses the splicing of exons
adjacent to the binding site. However, the sequence of the binding
sites of PTBP1 to pre-mRNA is conserved and cannot explain the
aberrant splicing events in cancer cells. Therefore, it is important
to identify PTBP1-interacting factors in cancer cells that could
modulate the interaction between the pre-mRNA and PTBP1,
leading to aberrant cancer-specific splicing events.
To identify the proteins that might be important for the
aberrant AS and tumorigenesis of HCC, we analyzed the tran-
scriptional dataset assembled from 225 HCC tissues and 220
non-cancerous liver tissues available in the Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/)
and discovered that the mRNA levels of the RNA helicase
MTR4 were increased in HCC tissues (Fig. 1a, b). We demon-
strated the important roles of MTR4 in promoting HCC
tumorigenesis and cancer metabolic reprogramming by
regulating HCC relevant AS events through recruiting PTBP1 to
its target pre-mRNAs. Our findings reveal the mechanisms
underlying aberrant AS events and cancer metabolic repro-
gramming in HCC, and provide a new therapeutic target for
treating HCC by inhibiting HCC relevant AS.
Results
MTR4 is required for the tumorigenesis of HCC cells. Con-
sistent with the mRNA expression data, immunohistochemical
analysis of MTR4 in 108 paired HCC tissues and adjacent non-
tumor (ANT) tissues indicated that the protein levels of MTR4 are
significantly higher in HCC samples than in ANT tissues (Fig. 1c, d,
Supplementary Fig. 1). To reveal the clinical relevance of the
expression levels of MTR4 in HCC, we analyzed the correlation
between the expression levels of MTR4 in the resected HCC tissues
and the prognosis of corresponding HCC patients, indicating that
the expression levels of MTR4 in HCC tissues are inversely corre-
lated with the recurrence-free survival (RFS) of HCC patients
(Fig. 1e, f). Univariate analysis indicates that the high expression
level of MTR4 is significantly associated with four-pathological
markers of HCC such as tumor size (p= 0.027), tumor number (p
= 0.006), MVI (p < 0.001), and differentiation (p= 0.043) (Table 1).
Analysis with Multivariate Cox proportional hazards model indi-
cates that the expression levels of MTR4 is an independent prog-
nostic marker for RFS of HCCs, after the adjustment for tumor size,
tumor number, MVI, and differentiation (Table 1).
To investigate the roles of MTR4 in the tumorigenesis of HCC,
we silenced the expression of MTR4 in two HCC cell lines, PLC/
PRF/5 cells and HepG2 cells, with distinct shRNAs (Fig. 1g,
Supplementary Fig. 2). The knockdown of MTR4 significantly
reduces the proliferation and colony-forming ability of HCC cells
(Fig. 1h, i, Supplementary Fig. 2b, c). Inducible knockdown of
MTR4 in HCC tumors already established in the immunodefi-
cient NODSCID mice greatly suppresses tumor growth (Fig. 1j–l,
Supplementary Fig. 2e, f). In contrast, doxycycline (Doxy) at the
given dosage has little effect on the tumor growth of HCC cells
expressing the scramble shRNA inducibly in NODSCID mice
(Fig. 1k, l). These data demonstrate that MTR4 is required for the
tumorigenesis of HCC cells.
MTR4 is required to maintain glycolysis of HCC cells. To reveal
the mechanism underlying MTR4-dependent tumorigenesis of
HCC cells, we performed RNA-seq analysis of HCC cells before
and after the inducible knockdown of MTR4 to identify the genes
that are affected by MTR4. Over 1249 genes were differentially
expressed (fold change > 2.0) between isogenic control and HCC
cells with MTR4 inducible knockdown. Based on KEGG-
functional annotation and gene ontology (GO) terms, the dif-
ferentially expressed genes (DEGs) are significantly enriched in
metabolic pathways (Supplementary Fig. 3). Using Consensus
path DB (CPDB), the DEGs are enriched in signaling and
metabolic pathways, especially glycolysis and carbohydrate
metabolism14 (Fig. 2a). Gene Set Enrichment Analysis (GSEA)
further reveals that glycolytic pathway is significantly deregulated
in the MTR4-depleted HCC cells (Supplementary Fig. 3). In this
context, the expression of several key glycolytic genes such as
GLUT1 and PKM2 was decreased in HCC cells after MTR4
knockdown (Fig. 2b). Doxycycline did not affect the expression of
these glycolytic genes in HCCs that inducibly expressed the
scramble shRNA, indicating that doxycycline at the used
dosage alone did not affect the expression of the metabolic genes
(Fig. 2b). Therefore, MTR4 is important to maintain the
expression of glycolytic genes in HCC cells.
Since MTR4 knockdown decreases the proliferation of HCC
cells, to evaluate the impact of MTR4 knockdown on metabolism,
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we synchronized the proliferation status of MTR4 knockdown
and control HCC cells by treating the cells with mitomycin C for
2 h (Supplementary Fig. 4). Consistent with the finding that the
MTR4 knockdown reduces the expression of glycolytic genes, the
silence of MTR4 expression decreased glycolytic activity and
increases oxidative phosphorylation, indicating that MTR4 drives
the metabolic shift from oxidative phosphorylation to glycolysis
(Fig. 2c–f). The knockdown of MTR4 reduced the expression of
the key glycolytic genes such as GLUT1 and PKM2 (Fig. 3a, b). To
understand the mechanism underlying MTR4-driven glycolysis
and tumorigenesis, we tested the hypothesis that the MTR4-
dependent expression of glycolytic genes is important for
mediating MTR4-driven tumorigenesis. Considering the impor-
tance of GLUT1 in cancer metabolism, we rescued the expression
levels of GLUT1 in the MTR4-silenced HCC cells through ectopic
expression of GLUT1 gene. The restoration of GLUT1 protein
levels in MTR4-silenced HCC cells partially rescued the defects in
glycolysis and cellular proliferation in vitro as well as tumor
growth in vivo (Fig. 3b–e, Supplementary Fig. 5). Therefore,
MTR4-dependent expression of glycolytic genes plays important
roles in driving cancer metabolism and tumorigenesis of HCC.
MTR4 regulates the alternative splicing (AS) in HCC cells. To
understand how MTR4 maintains the expression of glycolytic
genes, we performed RNA immunoprecipitation followed by
sequencing (RIP-seq) to identify the pre-mRNAs bound by
MTR4 in HCC cells. MTR4 binds to the intronic region of half of
the bound transcripts (1619/3301), suggesting that pre-mRNA is
the primary target bound by MTR4 (Supplementary Fig. 6a).
Consistent with the RNA-seq data, KEGG-functional annotation
analysis reveals that the transcripts bound by MTR4 are sig-
nificantly enriched in metabolism and cell cycle pathways
(Supplementary Fig. 6b, c). Using motif analysis tools such as
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MEME-Chip to screen for putative MTR4 binding motifs15, two
MTR4 binding motifs have been identified: (UAAAAAA(U)AA
(C)A(U)AA), the expected motif considering that MTR4 is a
helicase unwinding poly-A tail sequence9, and motif CCAG(C)
(U)C that is found in intronic region of pre-mRNA (Fig. 4a).
While previous studies have shown that MTR4 plays an
important role in RNA surveillance and RNA stability8,16, we
hypothesized that MTR4 might also regulate mRNA levels by
regulating the alternative splicing of pre-mRNAs. To test this
hypothesis, we analyzed the global mRNA splicing in HCC cells
before and after MTR4 depletion. We identified differential
alternative splicing (AS) events between the two sample groups
(KD vs Control) corresponding to all five basic types of AS
patterns, resulting with 1713 skipped exon (SE), 131 alternative
5′ splice site (A5SS), 192 alternative 3′ splice site (A3SS), 307
mutually exclusive exons (MXE), and 103 retained intron (RI)
differential AS events (Supplementary Fig. 6f). We used DAVID
(https://david.ncifcrf.gov/home.jsp, version 6.8) to perform
REACTOME pathway analysis for the identified genes, indicating
that the differential AS genes are enriched in the metabolic
pathways (Supplementary Fig. 6c). To evaluate the potential
significance of MTR4 in inducing the abnormal AS events in
HCC samples from patients, we compared the potential target
genes of MTR4 with the genes undergoing abnormal AS in HCC
cells after MTR4 KD. Our analysis indicates significant overlap
between the predicted MTR4 target genes with the genes
undergoing change in AS in HCC cells after MTR4 KD,
suggesting that the overexpression of MTR4 in HCCs plays a
key role in inducing abnormal AS in HCC of patients10
(Supplementary Fig. 6d, e).
MTR4 regulates AS by recruiting PTBP1 to its target pre-
mRNAs. To elucidate the mechanism how MTR4 regulates AS in
HCC cells, we focused on the key glycolytic genes GLUT1 and
PKM2, both are MTR4 targets as confirmed by the presence of
MTR4 binding motifs in their pre-mRNAs and by the standard
RIP assays, indicating that MTR4 binds to the intronic regions of
pre-mRNAs of these genes (Fig. 4b–e). After MTR4 knockdown,
the AS of the pre-mRNA of these genes is affected so that the
levels of mRNA encoding the functional GLUT1 and PKM2 are
reduced (Fig. 4f, g). In contrast, the levels of the alternatively
spliced mRNA isoforms, GLUT1b, a novel alternative spliced
GLUT1 mRNA, or PKM1, are increased (Fig. 4f, g).
To determine whether MTR4 binds to the pre-mRNA via the
predicted binding motifs, we constructed minigenes of GLUT1 and
PKM2 genomic DNA that contains exons flanking the introns with
the predicted MTR4 binding sites. Consistent with the data from
the endogenous genes, the knockdown of MTR4 increases the
splicing of the pre-mRNA transcribed from the minigenes to the
GLUT1b and PKM1 isoforms, indicating that these minigenes
could serve as a model to study the mechanisms how MTR4
regulates AS (Fig. 4h, i). In this context, the mutation of the
predicted MTR4 binding motifs within the minigenes abolishes the
binding of MTR4 to the pre-mRNA transcribed from these
minigenes, confirming that MTR4 binds to the predicted binding
Fig. 1 MTR4 is required for the tumorigenesis of HCC cells. a Heat map of the global mRNA expression profile in non-tumor tissues (n= 220) and
hepatocellular carcinoma (HCC) tissues (n= 225) in GSE14520 dataset. The levels of MTR4 are indicated with a white line. b Box plot showing the relative
mRNA levels of MTR4 in HCC tissues (n= 225) and non-tumor tissues (n= 220) in GSE14520 (GPL3921) dataset. The significance of the difference was
assessed by two-tailed, unpaired t-test. p value is indicated. Centre is median within box, bound of the box spans the interquartile range, and whiskers
visualize 5 and 95% of the data points. c, d Chips of HCC samples (n= 108) and adjacent non-tumor (ANT) samples (n= 108) were stained with anti-
MTR4 antibody and the intensity of staining was scanned and scored. Representative immunohistochemistry (IHC) images are shown. Two-tailed,
unpaired t-test. Data are presented as mean value ± s.d. p value is indicated. Scale bar= 200 µm. e The MTR4 mRNA levels in HCC samples (n= 77) were
compared with the corresponding ANT samples (n= 77). Eighty-three percent (64/77) of HCC samples have higher MTR4 mRNA levels than ANT. f The
MTR4 levels were inversely correlated with the postoperative recurrence-free survival (RFS) of HCC patients. RFS of the patients with high MTR4 mRNA
levels (n= 12) is significantly lower than those with lower MTR4 (n= 50). The difference in survival rates was assessed with the log-rank test (Mantel
Cox). p value is indicated. g The knockdown of MTR4 in HCC cells PLC/PRF/5 was confirmed by western blotting. CTL, HCC cells expressing scramble
shRNA. Tubulin was used as an internal control. Consistent data were obtained from two independent experiments. h Proliferation of MTR4 KD and control
cells was analyzed with CCK8 assay. n= 3 biologically independent experiments. Difference between two groups was calculated by two-way ANOVA,
followed by Bonferroni post-tests. Data are presented as mean value ± s.d. p value is indicated. i Colony formation assay of the control and MTR4 KD cells.
Difference between two groups was calculated by two-tailed, unpaired t-test. Data are presented as mean value ± s.d. p value is indicated. n= 3 biologically
independent samples. j Inducible knockdown of MTR4 in PLC/PRF/5 cells (iMTR4 cells) was confirmed by western blotting after the treatment with 1 µg/
ml doxycycline (Doxy) for 4 days. Consistent data were obtained from two independent experiments. k, l The volumes (k) and weight (l) of tumors formed
by PLC/PRF/5 cells expressing scramble shRNA (iSC) or iMTR4 cells in NSG mice were measured after daily i.p. injection of Doxy (20mg kg−1 body
weight) or mock treatment for 8 days. Individual tumor volumes were measured every day after doxy treatment. Repeated measures two-way ANOVA,
followed by Turkey’s post-tests. p value is indicated. Repeated measures two-way ANOVA, followed by Bonferroni post-tests. Data are presented as mean
value ± s.d. p value is indicated. n= 6 independent samples for each group. At the end of the treatment, the weight of all tumors in each group was
compared. Mann–Whitney test. p value is indicated. n= 6 independent samples for each group. Source data are provided as a Source Data file.
Table 1 Univariate and multivariate Cox regression analyses
of recurrence-free survival for MTR4 (n= 62).
Variables HR 95% CI P value
Univariate analysis
Age (<60 vs ≥60 years) 0.385 0.144–1.027 0.057
Gender (male vs female) 0.535 0.186–1.536 0.245
AFP (<400 vs ≥400) 1.691 0.853–3.352 0.133
Liver cirrhosis (yes vs no) 0.859 0.375–1.966 0.719
Capsule (yes vs no) 0.913 0.374–2.232 0.843
Tumor size (<5 vs ≥5 cm) 2.304 1.097–4.837 0.027
Tumor number (n= 1 vs n≥ 2) 3.310 1.412–7.756 0.006
MVIa (yes vs no) 4.697 2.094–10.536 <0.0001
PVTTb (yes vs no) 1.982 0.948–4.144 0.069
Differentiation (well,
moderate, poor)
0.527 0. 283–0.980 0.043
Expression of MTR4 (high vs low) 4.081 1.780–9.353 0.0001
Multivariate analysis
Tumor number 5.130 1.992–13.207 0.001
MVI (yes vs no) 7.358 2.799–19.341 0.000
PVTT (yes vs no) 0.472 0.195–1.144 0.682
MTR4 expression (high vs low) 5.414 1.968–14.891 0.001
Size_5 2.147 0.945–4.875 0.068
Differentiation 1.471 0.720–3.006 0.289
aMicro-vascular invasion.
bPortal vein tumor thrombosis.
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motifs of the pre-mRNA (Fig. 4j, k). In addition, similarly to the
impact of MTR4 knockdown, the mutation of the MTR4
binding motifs within the minigenes led to increased splicing of
the pre-mRNAs transcribed from the minigenes to GLUT1b
and PKM1 isoforms respectively, indicating that the binding of
MTR4 to its target pre-mRNA is required for its function in AS
(Fig. 5a, b).
To understand how MTR4 regulates AS events, we examined
the functional relationship between MTR4 and PTBP1, which is a
key regulator of AS13. While the overexpression of MTR4
induced the splicing of pre-mRNA transcribed from PKM
minigene to PKM2 isoform in HCC cells, the silence of PTBP1
in HCC cells inhibits the AS of the pre-mRNA transcribed from
PKM minigene to PKM2, suggesting that PTBP1 is involved in
MTR4-dependent splicing events (Fig. 5c). In support of this
notion, co-immunoprecipitation experiments indicate that MTR4
interacts with PTBP1 in a RNA-independent manner (Fig. 5d). In
contrast, MTR4 interacts with another RNA-binding protein
hnRNPA1 in a RNA-dependent manner (Fig. 5d). Therefore,
MTR4 might recruit PTBP1 to its target pre-mRNAs through
protein–protein interaction. In further support of this notion, the
mutation of the MTR4 binding motifs within the PKM minigene
significantly reduces the binding of PTBP1 to the pre-mRNA
transcribed from the minigene (Fig. 5e). In summary, these data
demonstrate that MTR4 regulates AS of its target genes by
recruiting PTBP1 to the target pre-mRNAs.
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Fig. 2 MTR4 is required for glycolysis of HCC cells. a Global gene expression analysis of iMTR4 cells before and after Doxy treatment identified
differential expressed genes (DEGs), which were enriched in various pathways with pathway analysis and visualized as the overlap graph. b The mRNA
levels of glycolytic genes in iSC and iMTR4 cells before and after Doxy treatment. Two-tailed, paired t-test. Data are presented as mean value ± s.d. p value
is indicated. n.s., non-significant. n= 3 biologically independent samples. c, d Extracellular acidification rate (ECAR) in control cells and MTR4 KD cells with
either MMC (5 µg/ml) or DMSO as a solvent control in response to glucose (10mM), oligomycin (1 μM), and 2-DG (50mM). n= 3 independent
experiments. Data are presented as mean value ± s.d., two-way ANOVA with a Tukey’s multiple comparison test. p value is indicated. e, f Oxygen
consumption rate (OCR) in control cells and MTR4 KD cells with either MMC or DMSO as a solvent control in response to oligomycin (1 μM),
fluorocarbonyl cyanide phenylhydrazone (FCCP, 1.5 μM), rotenone/antimycin A (Rot/AA, 0.5 μM). n= 3 independent experiments for each group. Data
are presented as mean value ± s.d., two-way ANOVA with Tukey’s multiple comparison test. p value is indicated. Res., respiration; Cap, capability. Source
data are provided as a Source Data file.
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c-Myc directly activates the transcription of MTR4 in cancer
cells. To further understand the importance of MTR4 pathway in
tumorigenesis of HCC, we searched for upstream regulators that
might activate MTR4 pathway. Because the critical oncoprotein c-
Myc promotes glycolysis partly by regulating AS of key glycolytic
genes such as PKM212,17, we examined the functional interaction
between c-Myc and MTR4. The analysis of the chromatin
immunoprecipitation-sequencing (ChIP-seq) data of c-Myc in sev-
eral cancer cells in the ENCODE database reveals that c-Myc binds
to the promoter of the MTR4 gene (Fig. 6a). This prediction is
confirmed by CHIP analysis, identifying a 695 bp CpG Isalnds
around TSS and two non-canonical E boxes (CACGCG, CACGAG)
that could be bound by c-Myc (Fig. 6b). The knockdown of c-Myc in
HCC cells reduces the expression of both mRNA and protein level of
MTR4, indicating that c-Myc directly activates the expression of
MTR4 (Fig. 6c, d). The physiological relevance of this finding is
further supported by the findings that the protein levels of c-Myc are
positively correlated with the levels of MTR4 in HCC tissues from
patients (Fig. 6e, f). In summary, MTR4 is a key downstream
mediator of c-Myc in promoting cancer metabolism of HCC.
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Fig. 3 Ectopic expression of GLUT1 rescued the defective tumorigenesis of HCC cells after MTR4 silencing. a Ectopic expression of GLUT1 in control and
MTR4 KD cells was analyzed for MTR4 and GLUT1 by western blotting. Representative data from two independent experiments are shown. b, c ECAR in
control cells and MTR4 KD cells transfected with either empty vector (EV) or plasmids expressing GLUT1 (GLUT1 OE) in response to glucose, oligomycin,
and 2-DG. Data are presented as mean value ± s.d., two-way ANOVA with a Tukey’s multiple comparison test. n= 3 independent experiments for each
group. d The proliferation of indicated cells were analyzed with CCK8 assay. Data are presented as mean value ± s.d. Two-way ANOVA with a Tukey’s
multiple comparison test. n= 3 independent biological samples. e The weight of tumors formed by indicated cells in NSG mice was measured and
compared. Data are presented as mean value ± s.d. One-way ANOVA, followed by Bonferroni post-tests. n= 8 independent biological samples for each
group. p value is indicated. Source data are provided as a Source Data file.
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Discussion
Both genetic and epigenetic abnormalities of cancer cells con-
tribute to cancer progression and drug resistance. Accumulating
data have indicated that cancer cells develop aberrant AS profile
that significantly increases the complexity of the oncogenic net-
work to promote tumorigenesis, but at the same time, provide
potential cancer-specific therapeutic targets11. Therefore, it is
critical to identify oncogenic pathways that induce the abnormal
AS events in human cancers. We discovered that the RNA heli-
case MTR4 is required for the tumorigenesis of HCC by main-
taining the expression of the key glycolytic genes in HCC cells.
MTR4 accomplishes this metabolic role by regulating AS of a
large panel of pre-mRNAs, including the ones transcribed from
the key glycolytic genes. Because MTR4 is overexpressed in a few
types of human cancers including HCC, and the target pre-
mRNAs of MTR4 are significantly overlapped with the pre-
mRNAs undergoing abnormal AS in HCC patient samples10,
MTR4 could be a master regulator of the oncogenic AS events in
HCC. Together with our finding that the acute depletion of
MTR4 in established HCC abolishes the tumor growth in vivo, we
propose that MTR4 could represent an effective and specific
therapeutic target for treating HCC.
As a RNA helicase, extensive studies have been devoted to
elucidate the biochemical roles of MTR4 in RNA processing, but
the roles of MTR4 in physiology and tumorigenesis remain
poorly understood. Previous studies have shown that the primary
roles of MTR4 include the binding to the 3′ UTR of a subset of
RNA such as viral RNA and target them for degradation, and
thus are involved in regulating RNA stability18. Our findings
reveal a novel role of MTR4 in AS, a highly regulated RNA
processing activity important for tumorigenesis. In this context,
MTR4 regulates AS by binding to the intronic region of pre-
mRNAs and recruiting PTBP1 to its target pre-mRNA through
protein–protein interaction. The pre-mRNAs targeted by MTR4
are enriched in metabolic and cell cycle pathways, indicating that
MTR4 has diversified and broad physiological and oncogenic
functions. In support of this notion, we demonstrate that MTR4-
dependent expression of glycolytic genes is important for glyco-
lysis and tumorigenesis of HCC cells, and MTR4 is an indepen-
dent prognostic marker for HCC. In this context, cancer cells also
develop alternative mechanisms to increase the expression of
glycolytic genes such as GLUT1 by epigenetics and to maintain
glycolysis by inducing PUMA-dependent suppression of oxida-
tive phosphorylation4,19.
The powerful and ubiquitous oncoprotein c-Myc is known to
promote cancer metabolic switch from oxidative phosphorylation
to glycolysis via multiple mechanisms such as the regulation of
AS of the key glycolytic genes including PKM217. It has been
reported that c-Myc induces the expression of PTBP1, hnRNPA1,
and hnRNPA2, resulting in exon 10 inclusion and PKM2 pro-
duction12. Our findings demonstrate that c-Myc directly activates
the expression of MTR4 in HCC cells and thus provide an
alternative mechanism how c-Myc regulates AS of glycolytic
genes in HCC in order to induce cancer metabolism. Considering
that c-Myc is overexpressed in a majority of human cancers and
promotes their tumorigenesis, but MTR4 is overexpressed in
limited types of human cancers, we predict that c-Myc is neces-
sary but not sufficient for activating the transcription of MTR4,
and other HCC-specific transcriptional factors are required to
collaborate with c-Myc in activating MTR4 transcription in HCC.
Methods
Patients and tissue samples. After obtaining adequate informed consent, hepa-
tocellular carcinoma (HCC) tissue and adjacent normal tissue (ANT, exceeding the
edge of the tumor by at least 2 cm) were obtained from 77 patients who underwent
curative resection for HCCs at Nanfang Hospital of Southern Medical University,
Guangzhou, China, between November 2010 and May 2015. Patients were reg-
ularly assessed for survival analysis via outpatient follow-up or telephone inter-
views. All patients satisfied the following inclusion criteria: they had not received
any other treatments before this surgery; the surgical margins were confirmed to
contain no residual carcinoma tissue; Clinicopathological information on age,
gender, tumor size, tumor number, tumor capsule, differentiation, AFP, Cirrhosis,
MVI (Micro-vascular), PVTT (invasion portal vein tumor thrombosis), TNM
stage, and BCLC stage was available. This study was approved by IRB of Nanfang
Hospital at Southern Medical University and was performed according to the
Declaration of Helsinki (6th revision, 2008).
All patient samples were immediately frozen in liquid nitrogen and stored at
−80 °C until the extraction of RNA. For the correlation study of mRNA expression
levels and survival time, total RNA was extracted from tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. cDNA
was synthesized using PrimeScript cDNA kit (Takara Bio, Kusatsu, Shiga, Japan).
Quantitative real-time PCR was performed using an SYBR Premix Ex Taq (Takara
Bio). 18S RNA levels were used as the internal control. The PCR primers were
listed in Supplementary Table 1. The correlation between the gene expression and
clinicopathological variables, including age, gender, tumor size, tumor number,
tumor capsule, differentiation, AFP, Cirrhosis, MVI, PVTT, TNM stage, and BCLC
stage was evaluated with the Chi-square test. Patients were divided into two groups
based on the MTR4 levels: patients with the top 25 percentile of the highest MTR4
expression in HCC and rest of the patients. The postoperative survival rate was
analyzed with the Kaplan–Meier method, and the difference in survival was
assessed with the log-rank test. Univariate and multivariate analyses were based on
the Cox proportional hazards regression model. All the statistical analyses were
performed with IBM SPSS Statistics 20.0 (IBM, IL, USA). Two-sided p values were
calculated, and p < 0.05 was considered a statistically significant result.
Cell lines, viral vectors, constructs, and transfection. 293 FT cell line was
purchased from Thermo Fisher Scientific (Waltham, MA). Other cell lines were
obtained from ATCC (American Type Culture Collection, USA) and maintained in
our laboratory. All cell lines were cultured at 37 °C with 5% CO2 in DMEM
(Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS) (Gibco,
Australia). To establish cells with stably silenced gene, lenti-viruses expressing
short hairpin RNA (shRNA) by the pLKO.1 puro vector were used (Addgene
#8453) according to Addgene’s pLKO.1 protocol. MTR4 shRNA target sequence is
GGAAGGATTTCCGATGGATTT. shRNA oligomers were designed, annealed,
and inserted into PLKO.1 puro according to Addgene’s pLKO.1 protocol. Lenti-
viruses were produced by co-transfecting the pLKO.1 vectors, packaging plasmid
psPAX2 (Addgene plasmid 12260, Addgene, Cambridge, MA) and envelope
plasmid pMD2.G (Addgene plasmid 12259) into HEK293FT cells. For the dox-
ycycline (Doxy)-inducible MTR4 knockdown, tet-pLKO-puro vector (Addgene
#21915) and Fuw-M2rtTA (Addgene 20342) were used. Seventy-two hours post
infection, cell debris in the media was removed by centrifugation at 2000 rpm for
10 min and lenti-virus concentrated by Lenti-X concentrator (Clonetech, Mountain
View, CA). One day before the viral infection, cells were plated into a six-well plate
at a density of 1 × 105 cells/well and transduced in the presence of 5 μg/ml poly-
brene for 72 h. The cells were selected for puromycin resistance (2 μg/ml) for
7 days. To overexpress Glut1, the full length of Glut1 cDNA was inserted into
pLenti-CMV GFP vector (Addgene 17448) linearized by Xba1 digestion.
AS analysis using minigene. Due to technical issues, PKM minigene was con-
structed by combining two fragments between intron 8 and intron 11 were sub-
cloned into the pLenti-CMV plasmid after PCR amplification using H1/H9 gDNA
as templates. All plasmid constructed in each step was confirmed by sequencing.
First fragments (3654 bp) were obtained by PCR using one primer pair hPKM-in8-
F01 and hPKM-R02 and modified for Gibson assembly by second round PCR
using one pair of primers hPKM-in8-gF and hPKM-R02-g. Modified fragments
were applied to Gibson assemble (NEBuilder HiFi DNA Assembly Master Mix)
with vector backbone plasmid pLenti-CMV GFP vector (Addgene 17448) linear-
ized and by BamHl/Sall digestion. Second fragments were obtained by PCR using
the primer pair hPKM-F02 and hPKM-in11-R, modified by PCR using another
primer pair hPKM-Frag2-gF2 and hPKM-gR, and applied to Gibson assembly with
pLenti-CMV vector including first fragment, which was prepared by Sall digestion
and rSAP-mediated dephosphorylation. Point mutations in MTR4 binding motifs
were introduced into minigenes by site-directed mutagenesis. For mutations in
poly-A tails, two primer pairs (PKM-m1766-F, PKM-m1766-R; PKM-m1906-F,
PKM-m1906-R), were used to amplify cDNA products, which were incubated with
methylation-dependent endonuclease Dpnl to remove parent template. For
mutating the short MTR4 binding motif, another two primer pairs (PKM-m1708-
F, PKM-m1708-R; PKM-m1906-F, PKM-m1906-R) were used.
Glut1 minigene was generated by PCR using the primer pair specific for intron
2 to intron 8 (hGlut1-in2-F, hGlut1-in8-R). Resulting products were modified for
Gibson assembly by the second round PCR using the pair of primers hGlut1-in2-gF
and hGlut1-in8-gR, and applied to Gibson assembly. Primers for site-directed
mutagenesis in the GLUT1 minigenes were Glut1m-F and Glut1m-R. For analysis
of alternative splicing in PKM and GLUT1 genes, PLC/PRF/5 cells were transfected
with plasmids expressing the indicated minigenes. Forty-eight hours later, RNA
was extracted, reversely transcribed, and applied to PCR detection for alternatively
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14437-3 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:708 | https://doi.org/10.1038/s41467-020-14437-3 | www.nature.com/naturecommunications 7
spliced forms. To distinguish minigene-derived transcripts from the endogenous
transcripts, reverse primers specific for plasmid backbone were used. Sequence of
all primers used in minigene analysis was provided in Supplementary Table 2.
Cell growth assay. For clonogenic assay, single-cell suspension was prepared by
trypsinization and the indicated cell lines seeded onto 6-well plates with a density
of 500 cells per well. After culturing for 2 weeks, colonies were stained with crystal
violet and counted. Cell Counting Kit 8 (CCK8) assay was performed using 96-well
plates. Briefly, cells were seeded at a density of 3–5 × 103 cells/well, and cultured for
24–96 h. CCK-8 solution was added to each well and incubated for 60 min, the
plates were measured at 450 nm with a microplate reader.
Animal experiments. All animal work was approved by Institutional Animal Care
and Use Committee (IACUC) of Southern Medical University and University of
California, San Diego. To analyze tumor growth in NODSCID mice, cells were
harvested, resuspended in 0.2 ml serum-free DMEM mixed with Matrigel at an 1:1
ratio, and injected subcutaneously into the left and right flank of NODSCID mice
(5 × 106 cells each). To evaluate the impact of MTR4 depletion on tumorigenicity,
mice bearing established tumors about 0.5 cm in diameter were randomized into
two groups. Subsequently, Doxy (20 mg/kg body weight) was injected intraper-
itoneally (i.p.) every day. The control group was injected with the same volume of
PBS. In addition, doxy-treated group was continuously provided with doxy con-
taining drinking water (2 mg/L).
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Extracellular acidification rate (ECAR). Glycolysis Stress Test (103020-100,
Agilent, Santa Clara, CA) was performed with the Seahorse XFe96 Extracellular
Flux Analyzer (Agilent, Santa Clara, CA). In total, 2 × 104 cells were plated onto
wells of a XF96 Cell Culture Microplate (102416-100, Agilent, Santa Clara, CA)
and incubated overnight. Plates were equilibrated in unbuffered XF assay medium
supplemented with 2 mM glutamine in the absence of CO2 for 1 h. Extracellular
acidification rates (ECAR) were assayed by the serial addition of Glucose (10 mM),
oligomycin (1 μM), and 2-deoxy-glucose (2-DG, 50 mM) to establish glycolysis
(ECAR in response to glucose− ECAR before glucose injection), glycolytic capacity
(ECAR in response to oligomycin− ECAR before glucose injection), glycolytic
reserve (glycolytic capacity− glycolysis), and non-glycolytic acidification (ECAR
before glucose injection). Each plotted value is the mean of at least 3 triplicate wells,
and normalized to baseline ECAR and total protein levels. Data were presented as
mean ± SD, and significance calculated by two-way ANOVA with Tukey’s multiple
comparison test.
Oxygen consumption rate (OCR). Cell Mito Stress Test (103015-100, Agilent,
Santa Clara, CA) was measured with the Seahorse XFe96 Extracellular Flux Ana-
lyzer (Agilent, Santa Clara, CA). In total, 2 × 104 cells were plated onto each well of
a XF96 Cell Culture Microplate (102416-100, Agilent, Santa Clara, CA) and
incubated overnight. The plates were equilibrated in unbuffered XF assay medium
supplemented with 10 mM glucose and 2 mM glutamine in the absence of CO2 for
1 h. Oxygen consumption rates (OCR) were interrogated by a serial addition of
oligomycin (1 μM), carbonyl cyanide 4‐(trifluoromethoxy) phenylhydrazone
(FCCP, 1.5 μM) and rotenone/antimycin A (Rot/AA, 0.5 μM) to establish basal
respiration (OCR before oligomycin injection−OCR in response to Rot/AA), ATP
production (OCR before oligomycin injection− OCR in response to oligomycin),
maximal respiration (OCR in response to FCCP−OCR in response to Rot/AA),
spare capacity (maximal respiration− basal respiration), and proton leak (OCR in
response to oligomycin−OCR in response to Rot/AA). Each plotted value is the
mean of at least three triplicate wells and normalized to baseline OCR and total
protein levels. Data are presented as mean ± SD, and significance calculated by two-
way ANOVA with Tukey’s multiple comparison test.
Western blotting and co-immunoprecipitation. Samples were separated on
8–15% SDS PAGE and transferred to nitrocellulose membranes. The blots were
incubated in blocking buffer (5% skim milk in PBS with 0.05% Tween 20) with
primary antibodies. After washing three times with blocking buffer, the blots were
probed with a horseradish peroxidase-conjugated secondary antibody and devel-
oped with Supersignal West Pico or Dura (Thermo Fisher Scientific). The following
antibodies were used: rabbit polyclonal anti-Myc antibody (13987; Cell Signaling),
rabbit polyclonal anti-MTR4 antibody (ab70551; Abcam), anti-Glut1 antibody
(ab150299; Abcam), mouse monoclonal anti-α-tubulin antibody (T5168; Sigma-
Aldrich), anti-rabbit IgG, HRP-linked antibody (7074S; Cell Signaling), anti-mouse
IgG antibody, HRP-linked antibody (7076S; Cell Signaling). For co-
immunoprecipitation (Co-IP), cell lysates were prepared in IP lysis buffer (87787,
Thermo) with Halt Protease and Phosphatase Inhibitor Cocktail (78430, Thermo)
on ice for 30 min. After centrifugation at 12,000 × g for 10 min at 4 °C, supernatants
were immunoprecipitated with either anti-hnRNPA1 (03-204, Millipore) or anti-
PTBP1 (MABE-986, Millipore) antibodies followed with magnetic protein A/G
beads (Pierce) for 2 h at 4 °C. The intensity of protein bands was quantified using
Image Lab (BioRad). All uncropped and unprocessed scans of western blots are
provided as Supplementary Fig. 7 in the Supplementary Information.
Quantitative PCR analysis. RNeasy Mini Kit (Invitrogen) was used to extract total
RNA from cells according to the manufacturer’s instructions. Cells were collected
directly into RLT lysis buffer and homogenized using QIAshredder (Qiagen)
according to manufacturer’s instructions. RNA was purified with RNeasy Mini kit
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columns, and genomic DNA removed with RNase-free DNase Kit (Qiagen). TRIzol
reagent (Thermo Scientific) was used for RNA extraction from human patient
tissues. 0.5 mg of liver tissues was homogenized in 1 ml TRIzol reagent with electric
homogenizer and mixed with 0.2 ml chloroform vigorously (Sigma-Aldrich). After
incubating at room temperature for 3 min, the mixture was centrifuged at 10,000 ×
g for 15 min. RNA fraction was mixed with the same volume of 100% ethanol and
purified with RNeasy column. cDNA synthesis from total RNA was performed
using High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems) fol-
lowing the manufacturer’s instructions. Real-time qPCR was performed with an
ABI Prism 7000 (Applied Biosystems) using FastStart Universal SYBR Green
Master (Takara). PCR conditions were following: 2 min at 95 °C, 40 cycles of 5 s at
95 °C, and 34 s at 60 °C. The average Ct value for each gene was determined from
triplicate reactions and normalized with mRNA levels of β-actin or 18 s. Sequence
of all primers used in qPCR analysis was provided in Supplementary Table 1.
RNA immunoprecipitation and sequencing (RIP-seq). RNA immunoprecipita-
tion (RIP) was carried out with Magna RIP RNA-Binding Protein immunopreci-
pitation kit (Millipore; USA) according to the manufacturer’s instruction. Cells
overexpressing MTR4-HA were lysed by RIP lysis buffer containing protease
inhibitor cocktail (Thermo Fisher, USA) and RNase inhibitor (Invitrogen, USA).
To obtain the plasmid expressing MTR4-HA, the full length of MTR4 cDNA was
amplified with primers tagged with HA sequence (TACCCATACGATGTTCCAG
ATTACGCT) and inserted into pcDNA3 vector that was linearized with Kpnl/Notl
digestion. Nuclear pellets were collected and lysed by sonication. Nuclear lysates
were incubated with anti-HA antibody or control IgG overnight at 4 °C, followed
by incubation with protein A/G Dynabeads (Thermo Fisher, USA) for 2 h. After
vigorous washing, pellets were resuspended in TRIzol (Invitrogen, USA). The
immunoprecipitated RNAs were purified by RNAeasy Mini Kit (Invitrogen),
reversely transcribed, and sequenced. All sequenced reads were checked with FasX-
Toolkit and the adapters removed with cutadapter. The processed reads were
mapped to hg19 whole genome using TopHat v2.0.13. Peak calling was performed
with RIPSeeker. The peak annotation was done with Homer, and the motifs bound
by MTR4 identified using MEME-ChIP. To evaluate the impact of MTR4 binding
motif on the interaction between RNAs of glycolytic genes and RNA-binding
proteins, cDNA derived from cells expressing either WT minigenes or minigenes
with mutations in MTR4 binding motifs were applied to PCR using a reverse
primer specific for the minigene vector. Sequence of all primers used in RIP-seq
analysis was provided in Supplementary Table 3.
Immunohistochemistry (IHC) analysis of tumor samples. Tumor samples were
fixed with 4% paraformaldehyde in 0.1 M phosphate buffer for 24 h, embedded in
paraffin, sliced into 4-μm sections and mounted onto glass slides. After dewaxing,
the slides were treated with 3% hydrogen peroxide in methanol and blocked with a
biotin-blocking kit (DAKO, Germany), incubated overnight with Ki67 monoclonal
antibody (1:50, BD Biosciences, USA) in a moist chamber at 4 °C. After washing
three times with PBS, the slides were incubated with biotinylated goat anti-mouse
antibodies for 1 h. The slides were stained with DAKO liquid 3,3′-diaminobenzi-
dine tetrahydrochloride (DAB), followed by their counterstaining with Mayer’s
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Fig. 6 MTR4 is a direct transcriptional target of c-Myc. a The analysis of Chip-seq data of c-Myc in human cancer cell lines available in the ENCODE
database predicted that c-Myc binds to the promoter region of MTR4. b ChIP analysis of the binding of c-Myc to the predicted c-Myc binding sites within
the MTR4 promoter. A schematic of MTR4 regulatory region (−0.7 to +1.3 kb from TSS) was shown. Arrow and black rectangle represent the
transcriptional start site (TSS) and exon1, respectively. * indicates the canonical E box. Green bar indicates CpG Islands. Numbers indicates the regions for
PCR. Chromatin DNA fragments were immunoprecipitated with anti-c-Myc antibody or IgG. Data are presented as mean values. n= 2 independent
experiments. c The mRNA levels of c-Myc and MTR4 were detected by q-RT-PCR and normalized by actin. Data are presented as mean values. n= 2
biologically independent samples. d The protein levels of c-Myc and MTR4 after the knockdown of c-Myc in HCC cells. Representative data from two
independent experiments are shown. e, f The protein levels of c-Myc and MTR4 in HCC patient samples were analyzed by western blotting (e) and their
correlation analyzed (f). The protein samples were run on multiple gels with one common sample run on all gels as a quantitative control. Two-tailed
Pearson correlation test. p value and pearson’s correlation coefficient r are indicated. n= 68 HCC patient samples. Source data are provided as a Source
Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14437-3
10 NATURE COMMUNICATIONS |          (2020) 11:708 | https://doi.org/10.1038/s41467-020-14437-3 | www.nature.com/naturecommunications
hematoxylin and examined under a microscope. The protein level of Ki67 was
determined by semi-quantitative IHC detection.
Cell cycle analysis. Cells were seeded onto 6-well plates at a density of 1 × 106
cells/well and treated with MMC (5 µg/ml) for 12 h. Cells were fixed with cold 70%
ethanol for 24 h at 4 °C and incubated with 0.5 mg/ml of propidium iodide (PI)
along with 0.1 mg/ml of RNase A (MultiSicences, China). Cell cycle analysis was
performed using a flow cytometry (FACScan, BD Biosciences), and analyzed with
the ModFIt LTV4.1.7 software (BD Biosciences). Cell debris and dead cells were
gated out for cell cycle analysis.
Chromatin immunoprecipitation (ChIP). After protein was cross-linked to DNA
with 1% formaldehyde, the nuclei were extracted and digested with Micrococcal
Nuclease to give rise to DNA fragments of ~150–600 bp. After immunoprecipi-
tation with anti-c-Myc antibody overnight at 4 °C, the crosslinking of the immu-
noprecipitated chromatin was reversed, and the amount of DNA in the
immunoprecipitate measured by qPCR.
RNA-seq analysis of alternatively spliced mRNA isoforms. We mapped RNA-
seq reads to the human genome (H. sapiens, GRCh38) and transcriptome
(Ensembl, release 84) using the software hisat2 (v2.1.0) with the default parameters.
The differential alternative splicing (AS) events between the two sample groups
(KD vs Control) were analyzed corresponding to all five basic types of AS patterns
using rMATS (rMATS). We ran rMATS with -c 0.0001 parameter and then
detected significant splicing events using a cutoff at FDR < 5% and |IncLe-
velDifference| ≥5%, resulting in 1713 SE, 131 A5SS, 192 A3SS, 307 MXE, and 103
RI differential AS events.
Quantification and statistic analysis. The statistical significance of Kaplan–Meier
survival plot was determined by log-rank analysis. Univariate and multivariate ana-
lyses were based on the Cox proportional hazards regression model. Statistical sig-
nificance in tumor growth rates was tested by repeated measure ANOVA. To
compare the tumor weights between two groups, non-parametric Mann–Whitney test
was used. For other experiments, significant difference was determined by t-test and
ANOVA. Asterisks indicate significant difference: ns, not significant. We assumed
normal distribution for the data having a small number. All statistical analyses of
patient’s survival were performed with IBM SPSS Statistics 20.0 (IBM). Other analyses
were performed with PRISM. N was indicated in the figure legends. No statistic
method was used for determining sample size, blinding and randomizing.
Biological materials availability. All biological materials can be obtained by
sending the request to the corresponding authors.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq data in Fig. 2a and Supplementary Fig. 3 are available in the NCBI Gene
Expression Omnibus (GEO) under the accession number GSE129263). The RIP-seq data
in Fig. 6a and Supplementary Fig. 5 are available in the NCBI Gene Expression Omnibus
(GEO) under GSE129261. The transcriptional dataset on 225 HCC tissues and 220 non-
cancerous liver tissues were obtained from Gene Expression Omnibus (GEO) database
under the accession number GSE14520. The images of uncropped and unprocessed
western blot and gels are included in the Supplementary Fig. 7. Source data underlying
Figs. 1c-f, 1h-i, 1k-l, Fig. 2b-f, Fig. 3b-e, Figs. 4c, 4e, 4h-k, Fig. 5a-b, Fig. 6b,
Supplementary Fig. 1, Supplementary Fig. 2b, c, e-h, k, Supplementary Fig. 5a-c, are
provided as a Source Data file.
Code availability
No custom scripts were used in the data analysis.
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